Literature DB >> 29299007

Apixaban Concentration with and without Coadministration of Carbamazepine: A Case with No Apparent Interaction.

Norelle Evanger1, Artur Szkotak2, Linda Stang3, Tammy J Bungard4.   

Abstract

Entities:  

Year:  2017        PMID： 29299007      PMCID： PMC5737190          DOI： 10.4212/cjhp.v70i6.1714

Source DB:  PubMed          Journal:  Can J Hosp Pharm        ISSN： 0008-4123


× No keyword cloud information.
  16 in total

1.  In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).

Authors:  X Wen; J S Wang; K T Kivistö; P J Neuvonen; J T Backman
Journal:  Br J Clin Pharmacol       Date:  2001-11       Impact factor: 4.335

2.  The antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liver.

Authors:  S Eyal; J G Lamb; M Smith-Yockman; B Yagen; E Fibach; Y Altschuler; H S White; M Bialer
Journal:  Br J Pharmacol       Date:  2006-08-07       Impact factor: 8.739

3.  Measurement of Anti-Factor Xa Activity in Patients on Apixaban for Non-Valvular Atrial Fibrillation.

Authors:  Hiroyuki Osanai; Masayoshi Ajioka; Tomohiro Masutomi; Tasuku Kuwayama; Sota Ishihama; Yusuke Sakamato; Naoya Otaka; Teruhiro Sakaguchi; Yosuke Inoue; Takahiro Kanbara; Yoshihito Nakashima; Hiroshi Asano; Kazuyoshi Sakai
Journal:  Circ J       Date:  2015-10-06       Impact factor: 2.993

Review 4.  Drug and dietary interactions of warfarin and novel oral anticoagulants: an update.

Authors:  Edith Nutescu; Ittiporn Chuatrisorn; Erika Hellenbart
Journal:  J Thromb Thrombolysis       Date:  2011-04       Impact factor: 2.300

5.  Direct oral anticoagulant drug level testing in clinical practice: A single institution experience.

Authors:  Karlyn Martin; Stephan Moll
Journal:  Thromb Res       Date:  2016-04-26       Impact factor: 3.944

6.  Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillation.

Authors:  Mika Skeppholm; Fadiea Al-Aieshy; Maria Berndtsson; Faris Al-Khalili; Yuko Rönquist-Nii; Lisbeth Söderblom; Annika Y Östlund; Anton Pohanka; Jovan Antovic; Rickard E Malmström
Journal:  Thromb Res       Date:  2015-04-30       Impact factor: 3.944

7.  Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways.

Authors:  Lukas Cerveny; Lucie Svecova; Eva Anzenbacherova; Radim Vrzal; Frantisek Staud; Zdenek Dvorak; Jitka Ulrichova; Pavel Anzenbacher; Petr Pavek
Journal:  Drug Metab Dispos       Date:  2007-03-28       Impact factor: 3.922

8.  Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: Results observed in four anticoagulation clinics.

Authors:  Sophie Testa; Armando Tripodi; Cristina Legnani; Vittorio Pengo; Rosanna Abbate; Claudia Dellanoce; Paolo Carraro; Luisa Salomone; Rita Paniccia; Oriana Paoletti; Daniela Poli; Gualtiero Palareti
Journal:  Thromb Res       Date:  2015-12-02       Impact factor: 3.944

9.  A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban.

Authors:  Charles Frost; Yan Song; Yu Chen Barrett; Jessie Wang; Janice Pursley; Rebecca A Boyd; Frank LaCreta
Journal:  Clin Pharmacol       Date:  2014-11-13

10.  Clinical implication of monitoring rivaroxaban and apixaban by using anti-factor Xa assay in patients with non-valvular atrial fibrillation.

Authors:  Kozue Ikeda; Hideaki Tachibana
Journal:  J Arrhythm       Date:  2015-09-15
View more
  3 in total

Review 1.  Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions.

Authors:  Sara R Vazquez
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Drug interactions with apixaban: A systematic review of the literature and an analysis of VigiBase, the World Health Organization database of spontaneous safety reports.

Authors:  Silvia Fernandez; Camille Lenoir; Caroline Samer; Victoria Rollason
Journal:  Pharmacol Res Perspect       Date:  2020-10

3.  The Problem With Predictions: A Cautionary Tale of Empirically Adjusting Apixaban Dosing With Carbamazepine.

Authors:  Ayush Chadha; David Lopaschuk; Margaret L Ackman; Tammy J Bungard
Journal:  CJC Open       Date:  2022-01-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.